India Pharma Outlook Team | Wednesday, 14 January 2026
Bristol Myers Squibb today reported positive Phase 3 results for Camzyos in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The data come from the Phase 3 SCOUT-HCM trial, the first study of a cardiac myosin inhibitor in patients aged 12 to 17.
The trial met its primary endpoint, showing a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT gradient) at Week 28 versus placebo, confirming Camzyos improves LVOT obstruction.
Several secondary endpoints also reached statistical significance, highlighting meaningful clinical improvements. Safety was consistent with the adult profile, with no new safety signals, and the study will continue into active treatment and long-term extension phases.
Also Read: Navigating the New Era of Nitrosamine Compliance
“Adolescent oHCM is a serious, rare disease associated with substantial morbidity and mortality. The SCOUT-HCM topline results highlight the potential for Camzyos to be the first cardiac myosin inhibitor for adolescent patients with oHCM,” said Cristian Massacesi, MD, executive vice president, Chief Medical Officer and Head of Development, Bristol Myers Squibb.
“The SCOUT-HCM study is important for patients and the field of pediatric cardiology, being one of the very few pediatric cardiology randomized and placebo-controlled clinical trials that has generated positive Phase 3 results,” said Joseph Rossano, Principal Investigator and Chief of the Division of Cardiology at Children’s Hospital of Philadelphia.
Backed by the largest global clinical and real-world evidence base in its class, Camzyos reduces cardiac hypercontractility by limiting excess myosin-actin cross-bridges in the heart’s sarcomere.
.jpg)
.jpg)
